Theorem Clinical Research

Ono Pharmaceutical

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015 11:45 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

More... »

Quest Diagnostics

International GPCR Consortium adds Novo Nordisk and Merck

Wednesday, February 11, 2015 12:34 PM

The GPCR Consortium, an international nonprofit collaboration that comprises academic research institutes in the U.S. and China and major pharma companies around the world, has announced Novo Nordisk and Merck as new members. The companies join AmgenSanofi and Ono in the GPCR Consortium. The research funded by the GPCR Consortium currently is conducted at the Bridge Institute at the University of Southern CaliforniaShanghai Institute of Materia Medica and the iHuman Institute at ShanghaiTech University.

More... »


Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin partner

Thursday, December 11, 2014 11:56 AM

Bristol-Myers Squibb and Japan-based companies Ono Pharmaceutical and Kyowa Hakko Kirin have entered into a clinical trial collaboration agreement to conduct a phase I combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors.

More... »

International GPCR Consortium formed with pharma, academia partners

Wednesday, October 29, 2014 01:32 PM

The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of a new international partnership. Called the GPCR Consortium, the nonprofit initiative brings together pharmaceutical companies and research institutes from three continents to advance GPCR research for drug development.

More... »

Bristol-Myers Squibb, Ono Pharmaceutical collaborate in Japan, South Korea, Taiwan

Monday, July 28, 2014 02:54 PM

Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

More... »

AMRI, Ono Pharma broaden Smartsourcing collaboration

Monday, April 29, 2013 11:21 AM

AMRI, a global contract research and manufacturing organization, has entered into a new five-year service agreement with Ono Pharmaceutical, a pharmaceutical company based in Osaka, Japan

More... »

Galapagos subsidiary BioFocus collaborates with Ono on CNS drug discovery

Tuesday, September 4, 2012 12:46 PM

Galapagos’ service division BioFocus and Ono Pharmaceutical have signed a new collaboration agreement focused on discovering novel drugs for CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates.

More... »

Drug reduced number of MS lesions in phase II trial

Wednesday, April 18, 2012 12:37 PM

An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase II clinical trial supported by Ono Pharmaceutical.

More... »

Tioga raises $10 million for irritable bowel syndrome trial

Friday, April 13, 2012 01:26 PM

Tioga Pharmaceuticals of San Diego has closed its $10 million Series B equity financing led by new investor Thomas, McNerney & Partners, which invested $8 million in the round.

More... »

Merck, Ono Pharmaceutical collaborate

Tuesday, October 4, 2011 01:33 PM

Merck Serono has signed two separate agreements with Ono Pharmaceutical, Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.

More... »


CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs